Zepbound Monitoring Schedule: Labs & Exams Your Prescriber Should Order
Plan regular check-ins during dose changes, with blood tests chosen for your health history and symptoms. An Endocrine Society guideline recommends assessing weight-loss medication safety and effectiveness at least monthly for the first three months, then at least every three months. This is a visit schedule, not a requirement to repeat a large laboratory panel at every appointment. [1]
A useful monitoring plan answers four questions: Is treatment helping? Are side effects manageable? Have other medicines become too strong as weight or glucose changes? Is there a symptom that needs assessment before the next scheduled visit?
A practical follow-up calendar
| Stage | Main purpose | What to bring |
|---|---|---|
| Before starting | Confirm treatment suitability, goals and relevant baseline measurements | Medication and supplement list, prior lab results, medical history and questions |
| First three months | Review response, eating and drinking, side effects and the next dose | Injection dates, current dose, weight trend and symptom notes |
| After a dose increase | Check tolerability before another change | Details of vomiting, diarrhea, constipation, dizziness or difficulty maintaining intake |
| Stable treatment | Review sustained benefit, nutrition, activity and other prescriptions | Progress toward your goals and any new diagnoses or medicines |
| New concerning symptoms | Arrange prompt assessment | Symptom onset, severity, last injection and medicines taken |
Ask the clinic to write down both the next appointment date and how to contact the team between appointments. A missed follow-up should be rescheduled rather than treated as permission to continue increasing the dose.
Before the first injection
Zepbound is approved for weight management in eligible adults and for moderate to severe obstructive sleep apnea in adults with obesity. It is not used in people with a personal or family history of medullary thyroid carcinoma, or MEN2. [2]
The starting assessment should connect your treatment goals with the conditions that matter for you. Bring information about diabetes, kidney problems, gallbladder disease, pancreatitis and significant digestive symptoms. [2,3]
Record a starting weight and discuss how progress will be measured. NIDDK describes weight-management medication as part of a longer-term plan that also includes eating habits and physical activity. Your follow-up can therefore include practical measures such as walking tolerance, meal regularity and whether treatment is affordable enough to continue. [4]
Which blood tests may be useful?
The reason for a test matters more than buying a fixed “Zepbound panel.” Use this table to discuss the specific question each proposed test will answer.
| Test or assessment | Clinical question |
|---|---|
| HbA1c or glucose | Is diabetes present, and how is an existing diabetes treatment plan working? |
| Kidney function and electrolytes | Has vomiting, diarrhea or poor fluid intake affected hydration or kidney function? |
| Lipid panel | Is an existing cholesterol or cardiovascular prevention plan working? |
| Liver tests | Does a known liver condition or another clinical finding need follow-up? |
| Thyroid testing | Is there a separate reason to evaluate thyroid function? |
| Symptom-directed examination or imaging | Does a new symptom need investigation now? |
A normal TSH does not screen for medullary thyroid cancer. Routine calcitonin measurement or thyroid ultrasound has uncertain value for early detection in people taking Zepbound. The prescribing information calls for kidney monitoring when adverse effects could cause dehydration and closer glucose monitoring when hypoglycemia is a concern. [2]
For any lab order, ask: “What result would change my treatment, and when will someone review it?” Keep the result and the follow-up decision together in your records.
Dose changes and other medicines
The label starts treatment at 2.5 mg weekly for four weeks. Further increases are separated by at least four weeks, with response and tolerability guiding the maintenance dose. Increasing the dose should be a planned decision, not an automatic response to one disappointing weigh-in. [2]
People taking insulin or a sulfonylurea need an agreed glucose plan. Oral contraception requires a non-oral method or an added barrier method for four weeks after starting and four weeks after each dose increase. [2]
Bring actual medicine names and doses to visits, including nonprescription products. MedlinePlus also recommends discussing oral medicines because tirzepatide slows stomach emptying. Ask the pharmacist which prescriptions need a specific monitoring plan rather than assuming that every medicine needs a new laboratory test. [3]
What progress looked like in the main weight-loss trial
SURMOUNT-1 randomized 2,539 adults with obesity or overweight plus a weight-related complication, without diabetes. At 72 weeks, average weight changes were -15.0%, -19.5% and -20.9% with tirzepatide 5, 10 and 15 mg, compared with -3.1% with placebo. Treatment included a 20-week dose-escalation period. Gastrointestinal effects were most common during escalation. [5]
That timeline makes repeated measurements more useful than a single early result. Bring the overall trend, missed doses and side effects to the visit. The prescriber can then distinguish a tolerability problem, an access problem and an inadequate treatment response.
Symptoms that should not wait for routine follow-up
Seek prompt medical care for persistent severe abdominal pain, especially if it spreads to the back; ongoing vomiting; yellow skin or eyes; or signs of dehydration. Report a neck lump, persistent hoarseness or swallowing difficulty. Follow the clinician's instructions about further doses while symptoms are evaluated. [3]
Frequently asked questions
Frequently asked questions
Do I need blood tests every month?
What should I track between visits?
Should I increase the dose if my weight stops changing for a week?
What if I cannot attend the next appointment?
References
- Endocrine Society. Pharmacological management of obesity guideline. Follow-up recommendations.
- Eli Lilly. Zepbound prescribing information. Revised August 2026.
- MedlinePlus. Tirzepatide injection. Patient instructions and symptoms requiring medical attention.
- NIDDK. Prescription medications to treat overweight and obesity.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022. SURMOUNT-1.